Aims and Scope of Expert Opinion on Drug Safety
Expert Opinion on Drug Safety is a monthly peer-reviewed medical journal publishing review articles on all aspects of pharmacovigilance and original papers on the clinical implications of drug treatment safety issues. It was established in 2002 and is published by Informa. The editor-in-chief is Roger McIntyre (University of Toronto). Less
Key Metrics
CiteScore 

6.1
Eigenfactor 

0.005 - 0.01
H-Index 

81
Impact Factor 

< 5
SJR 

Q2Pharmacology (medical)

SNIP 

1.17
Recommended pre-submission checks
Powered by 

Topics Covered on Expert Opinion on Drug Safety
Expert Opinion on Drug Safety Journal Specifications
| Overview | |
| Publisher | TAYLOR & FRANCIS LTD |
| Language | English |
| Frequency | Bi-monthly |
| General Details | |
| Language | English |
| Frequency | Bi-monthly |
| Publication Start Year | 2002 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Expert Opinion on Drug Safety ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations

Recently Published Papers in Expert Opinion on Drug Safety
Could anticholinergics accelerate ALS progression? A critical perspective on drug safety and disease vulnerability.
- 30 Jun 2026
- Expert opinion on drug safety
Safety profile of teprotumumab-trbw, the first and only FDA-approved treatment for thyroid-associated ophthalmopathy
- 26 Jun 2026
- Expert Opinion on Drug Safety
A systematic review and meta-analysis of safety and efficacy parameters of sotatercept in the therapy of pulmonary arterial hypertension
- 12 Jun 2026
- Expert Opinion on Drug Safety
Tirzepatide data: safety first is safety always!
- 4 Jun 2026
- Expert Opinion on Drug Safety
An update on the safety of biologics for the treatment of psoriasis
- 21 May 2026
- Expert Opinion on Drug Safety
Recent advances in trastuzumab and its antibody-drug conjugates-related liver injury
- 18 May 2026
- Expert Opinion on Drug Safety
Could anticholinergics accelerate ALS progression? A critical perspective on drug safety and disease vulnerability.
- 30 Jun 2026
- Expert opinion on drug safety
Safety profile of teprotumumab-trbw, the first and only FDA-approved treatment for thyroid-associated ophthalmopathy
- 26 Jun 2026
- Expert Opinion on Drug Safety
A systematic review and meta-analysis of safety and efficacy parameters of sotatercept in the therapy of pulmonary arterial hypertension
- 12 Jun 2026
- Expert Opinion on Drug Safety
Tirzepatide data: safety first is safety always!
- 4 Jun 2026
- Expert Opinion on Drug Safety
An update on the safety of biologics for the treatment of psoriasis
- 21 May 2026
- Expert Opinion on Drug Safety
Recent advances in trastuzumab and its antibody-drug conjugates-related liver injury
- 18 May 2026
- Expert Opinion on Drug Safety